{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Recurrence or progression of the malignant disease that was the reason for hematopoietic cell transplantation","groups":[{"description":"Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treated Patients"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years after enrollment","title":"Recurrent or Progressive Malignancy","type":"SECONDARY","unitOfMeasure":"Participants"}